// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























45280 Abstracts

Laparoscopic left pancreatectomy in a UK tertiary centre; analysis of a 5 year experience

N.G. Mowbray - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Initial Experience in Irreversible Electroporation of Unresectable Pancreatic Cancer

T. Tsirlis - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Extended versus standard lymphadenectomy for pancreatic head cancer: Systematic-review and meta-analysis

B.V. Dasari - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Drainage of postoperative pancreatic collections after pancreatic surgery by endoscopic ultrasound-guided approach

G. Turri - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Outcomes following resection of metastatic disease to the pancreas

M. Pitchaimuthu - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Is routine supplementation of pancreatic exocrine enzymes following pancreaticoduodenectomy justified?

B. Dasari - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Inoperable carcinoma of pancreas – the need for coordinated care to allow a ‘Good Death’

D. Hughes - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Laparoscopic distal pancreatectomy – Its application in clinical practice

E. Dorrian - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Comprehensive multi-component learning curve analysis of a single-surgeon series of laparoscopic distal pancreatectomy: Outcomes improve even with increasing complexity of cases

A.P. Belgaumkar - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Long interval radiological surveillance of side branch pancreatic duct-involved intraductal papillary mucinous neoplasm in selected patients

Y.S. Khaled - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Intraductal papillary mucinous neoplasm

N/A

Does obesity increase the post-operative morbidity following a pancreatico-duodenectomy?

M. Rawashdeh - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Obesity

N/A

Monocarboxylate transporter upregulation supporting the reverse warburg effect in the tumour microenvironment of pancreatic ductal adenocarcinoma

J. Moir - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

A model to predict survival following pancreaticoduodenectomy for malignancy based on tumour site, stage and lymph node ratio

B.V. Dasari - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Gemcitabine-loaded and antibody-tagged superparamagnetic iron oxide nanoparticles as targeted drug vehicles in pancreatic cancer cell lines

S. Nandi - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

Gemcitabine

The effect of a pancreatic anastomosis leak on long-term survival after pancreaticoduodenectomy for ampullary cancers, distal cholangiocarcinomas and pancreatic ductal cancers

A. Sewpaul - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Advanced biliary tract carcinoma

N/A

Arterial resection in T4 adenocarcinoma of the pancreas

R. Ravikumar - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Assessement of a safe interval between radiological staging and surgical resection for resectable pancreatic malignancy

G. Alessandri - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Staging laparoscopy for periampullary carcinoma at a tertiary pancreaticobiliary centre

M.P. Horner - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Peri-operative inflammation as judged by the neutrophil-lymphocyte ratio (NLR) has no impact on survival following resection of pancreatic ductal adenocarcinoma (PDAC)

S.M. Robinson - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreas ductal adenocarcinoma

N/A

Audit of emergency presentation of pancreatic cancer

D. Ojo - International Hepato-Pancreato-Biliary Association (IHPBA) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Pancreatic cancer

N/A

Copyright © 2026. QuantiNova All rights reserved